Physician profile
Deborah A Harrell
NPI 1275960254
$1,644.05
in general payments reported to CMS, 2019-2025
35 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $649 · 2022: $204 · 2023: $270 · 2024: $238 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $199.96 | 2021-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $180.23 | 2021-2022 | |
| Lilly USA, LLC | $164.18 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $102.95 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $100.22 | 2021-2025 | Austedo Xr, Austedo Xr |
| Novo Nordisk INC | $97.92 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $57.23 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $56.51 | 2023-2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.21 | 2021-2024 | Jardiance |
| Nevro Corp. | $44.52 | 2023 | Senza |
| Clarus Therapeutics INC. | $41.77 | 2021 | |
| Exact Sciences Corporation | $40.51 | 2024-2025 | Cologuard Collection Kit |
| Almatica Pharma LLC | $40.48 | 2021-2025 | Loreev Xr, Teriparatide |
| Neurelis, INC. | $33.53 | 2023 | Valtoco |
| Glaxosmithkline, LLC. | $33.50 | 2023-2024 | Arexvy, Shingrix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.97 | 2021 | |
| Neurocrine Biosciences, INC. | $28.83 | 2023 | Ongentys, Ingrezza |
| Janssen Pharmaceuticals, INC | $25.21 | 2025 | Spravato |
| Lundbeck LLC | $24.35 | 2024 | Rexulti |
| Alexion Pharmaceuticals, INC. | $24.17 | 2025 | Strensiq |
| Astellas Pharma US INC | $24.17 | 2021 | |
| Ge Healthcare | $22.42 | 2022 | |
| Dexcom, INC. | $21.79 | 2022 | |
| Nestle Healthcare Nutrition INC. | $20.98 | 2021 | |
| Amarin Pharma, INC. | $20.17 | 2022 | |
| Optos, INC. | $19.47 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.32 | 2023 | |
| Virtus Pharmaceuticals LLC | $17.80 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.34 | 2021 | |
| Mylan Specialty L.P. | $16.49 | 2021 | |
| Azurity Pharmaceuticals, INC. | $16.01 | 2024 | |
| Endo Pharmaceuticals INC. | $15.78 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.47 | 2025 | Rexulti |
| Daiichi Sankyo INC. | $13.19 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.